On-Demand Webinar | Subcellular Proteomic Imaging Using Multiplexed Ion Beam Imaging (MIBI)

Subcellular Proteomic Imaging Using Multiplexed Ion Beam Imaging (MIBI)

Presented by: Dr. Jay Tarolli, Director of Product Development, Ionpath

Originally aired October 26, 2023

Abstract

Multiplexed ion beam imaging (MIBI) has been developed by Stanford University and Ionpath to enable researchers to image 40+ proteins in tissue samples with subcellular spatial resolution at a throughput that makes large-scale cohort studies feasible. Based on time-of-flight secondary ion mass spectrometry (ToF-SIMS), MIBI overcomes many of the challenges faced when studying biological tissue samples, specifically for protein analysis, by performing targeted proteomic measurements with metal conjugated antibodies. Metal atoms, generally from the lanthanide series, are used as reporters by linking them to antibodies that will specifically bind to protein targets. ToF-SIMS enables parallel detection of 40+ such reporter atoms, resulting in a highly multiplexed proteomic analysis technique that can phenotype 50+ cell types in a single scan. Ionpath develops the entire platform needed to perform highly multiplexed proteomic imaging, including the metal conjugated antibodies, ToF-SIMS instrumentation, software for data acquisition and analysis, and bioinformatics tools for cell phenotyping and spatial analysis of tissue images. While the MIBI platform has been focused on investigating and profiling the tumor microenvironment for cancers and immune response to cancers, the technology can be applied to many other disease areas, including recent work in neuropathology and HIV.

Contact Us

<p style="text-align: center; margin-top: 2em;">Let us know how we can help you.</p>


    Immuno-oncology/CancerNeuroscienceInfectious DiseaseImmunologyStem CellOther

    255

    Please contact me. I understand that I can choose to unsubscribe at any time by e-mailing marketing@ionpath.com.

    X
    Contact Us

    We are using cookies on our website

    Please confirm, if you accept our tracking cookies. You can also decline the tracking and continue to visit our website without any data sent to third-party services.